Search
Now showing items 1-2 of 2
OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance
(2012)
OSI-930, a dual c-Kit and KDR tyrosine kinase inhibitor, is reported to have undergone a Phase I dose escalation study in patients with advanced solid tumors. A series of fifteen pyridyl and phenyl analogues of OSI-930 ...
Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930
(2011)
The quinoline domain of OSI-930, a dual inhibitor of receptor tyrosine kinases (RTKs) c-Kit and KDR, was modified in an effort to further understand the SAR of OSI-930, and the binding site characteristics of c-Kit and ...